Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral LP-108 in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
CTR20261956Phase 2Active
- Sponsor
- Lupeng Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lacutoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Lupeng Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
lacutoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20261956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261956.